Jianya Zhou

ORCID

Publication Activity (10 Years)

Years Active: 2021-2024
Publications (10 Years): 24

Top Venues

Nature communications

Cancer communications (London, England)

NPJ precision oncology

Technology in cancer research & treatment

This page only lists publications with an associated author ORCID identifier.

Publications

Fengqi Qiu, Peishan Jiang, Guiheng Zhang, Jie An, Kexin Ruan, Xiaowen Lyu, Jianya Zhou, Wanqiang Sheng
Priming with LSD1 inhibitors promotes the persistence and antitumor effect of adoptively transferred T cells. Nature communications 15 (1) (2024)
Chunwei Xu, Zhanhong Chen, Yuanli Xia, Yanxia Shi, Peifen Fu, Yi-Ding Chen, Xian Wang, Lili Zhang, Hengyu Li, Wenyan Chen, Jianfei Fu, Liming Huang, Jingde Shu, Ouchen Wang, Weizhu Wu, Bojian Xie, Ting Wang, Weiping Zhang, Shurong Shen, Qun Li, Ting Luo, Bin Zhang, Yanru Xie, Hongxia Wang, Qian Wang, Wen-Xian Wang, Ziming Li, Zhengbo Song, Wenfeng Fang, Wen-Zhao Zhong, Yongchang Zhang, Ping Zhan, Hongbing Liu, Tangfeng Lv, Li-Yun Miao, Lingfeng Min, Feng Wang, Rui Meng, Youcai Zhu, Lin Wang, Bing Wan, Dong Wang, Yue Hao, Jianya Zhou, Long Huang, Zhang Zhang, Donglai Lv, Meiyu Fang, Yuanzhi Lu, Lu Si, Yong Song, Xiaojia Wang
Clinical best practices in interdisciplinary management of human epidermal growth factor receptor 2 antibody-drug conjugates-induced interstitial lung disease/pneumonitis: An expert consensus in China. Cancer (2024)
Cuihong Cai, Qian Shen, Jingjing Shao, Jingjing Qu, Shuangshuang Zhou, Jianya Zhou
Efficacy and Safety of Anlotinib in EGFR-Positive Patients with Advanced Lung Adenocarcinoma Compared with Chemotherapy: A Retrospective Study. Technology in cancer research & treatment 23 (2024)
Jing Zheng, Tao Wang, Yunpeng Yang, Jie Huang, Jifeng Feng, Wu Zhuang, Jianhua Chen, Jun Zhao, Wei Zhong, Yanqiu Zhao, Yiping Zhang, Yong Song, Yi Hu, Zhuang Yu, Youling Gong, Yuan Chen, Feng Ye, Shucai Zhang, Lejie Cao, Yun Fan, Gang Wu, Yubiao Guo, Chengzhi Zhou, Kewei Ma, Jian Fang, Weineng Feng, Yunpeng Liu, Zhendong Zheng, Gaofeng Li, Huijie Wang, Shundong Cang, Ning Wu, Wei Song, Xiaoqing Liu, Shijun Zhao, Lieming Ding, Giovanni Selvaggi, Yang Wang, Shanshan Xiao, Qian Wang, Zhilin Shen, Jianya Zhou, Jianying Zhou, Li Zhang
Updated overall survival and circulating tumor DNA analysis of ensartinib for crizotinib-refractory ALK-positive NSCLC from a phase II study. Cancer communications (London, England) 44 (4) (2024)
Wenjia Sun, Fengqi Qiu, Jing Zheng, Liangjie Fang, Jingjing Qu, Shumeng Zhang, Nan Jiang, Jianying Zhou, Xun Zeng, Jianya Zhou
CD57-positive CD8 + T cells define the response to anti-programmed cell death protein-1 immunotherapy in patients with advanced non-small cell lung cancer. NPJ precision oncology 8 (1) (2024)
Jing Zheng, Tao Wang, Yunpeng Yang, Jie Huang, Jifeng Feng, Wu Zhuang, Jianhua Chen, Jun Zhao, Wei Zhong, Yanqiu Zhao, Yiping Zhang, Yong Song, Yi Hu, Zhuang Yu, Youling Gong, Yuan Chen, Feng Ye, Shucai Zhang, Lejie Cao, Yun Fan, Gang Wu, Yubiao Guo, Chengzhi Zhou, Kewei Ma, Jian Fang, Weineng Feng, Yunpeng Liu, Zhendong Zheng, Gaofeng Li, Huijie Wang, Shundong Cang, Ning Wu, Wei Song, Xiaoqing Liu, Shijun Zhao, Lieming Ding, Giovanni Selvaggi, Yang Wang, Shanshan Xiao, Qian Wang, Zhilin Shen, Jianya Zhou, Jianying Zhou, Li Zhang
Updated overall survival and circulating tumor DNA analysis of ensartinib for crizotinib-refractory ALK-positive NSCLC from a phase II study. Cancer communications (London, England) 44 (4) (2024)
Jing Zheng, Tao Wang, Yunpeng Yang, Jie Huang, Jifeng Feng, Wu Zhuang, Jianhua Chen, Jun Zhao, Wei Zhong, Yanqiu Zhao, Yiping Zhang, Yong Song, Yi Hu, Zhuang Yu, Youling Gong, Yuan Chen, Feng Ye, Shucai Zhang, Lejie Cao, Yun Fan, Gang Wu, Yubiao Guo, Chengzhi Zhou, Kewei Ma, Jian Fang, Weineng Feng, Yunpeng Liu, Zhendong Zheng, Gaofeng Li, Huijie Wang, Shundong Cang, Ning Wu, Wei Song, Xiaoqing Liu, Shijun Zhao, Lieming Ding, Giovanni Selvaggi, Yang Wang, Shanshan Xiao, Qian Wang, Zhilin Shen, Jianya Zhou, Jianying Zhou, Li Zhang
Updated overall survival and circulating tumor DNA analysis of ensartinib for crizotinib-refractory ALK-positive NSCLC from a phase II study. Cancer communications (London, England) 44 (4) (2024)
Chunwei Xu, Zhanhong Chen, Yuanli Xia, Yanxia Shi, Peifen Fu, Yi-Ding Chen, Xian Wang, Lili Zhang, Hengyu Li, Wenyan Chen, Jianfei Fu, Liming Huang, Jingde Shu, Ouchen Wang, Weizhu Wu, Bojian Xie, Ting Wang, Weiping Zhang, Shurong Shen, Qun Li, Ting Luo, Bin Zhang, Yanru Xie, Hongxia Wang, Qian Wang, Wen-Xian Wang, Ziming Li, Zhengbo Song, Wenfeng Fang, Wen-Zhao Zhong, Yongchang Zhang, Ping Zhan, Hongbing Liu, Tangfeng Lv, Li-Yun Miao, Lingfeng Min, Feng Wang, Rui Meng, Youcai Zhu, Lin Wang, Bing Wan, Dong Wang, Yue Hao, Jianya Zhou, Long Huang, Zhang Zhang, Donglai Lv, Meiyu Fang, Yuanzhi Lu, Lu Si, Yong Song, Xiaojia Wang
Clinical best practices in interdisciplinary management of human epidermal growth factor receptor 2 antibody-drug conjugates-induced interstitial lung disease/pneumonitis: An expert consensus in China. Cancer 130 (S17) (2024)
Jing Zheng, Tao Wang, Yunpeng Yang, Jie Huang, Jifeng Feng, Wu Zhuang, Jianhua Chen, Jun Zhao, Wei Zhong, Yanqiu Zhao, Yiping Zhang, Yong Song, Yi Hu, Zhuang Yu, Youling Gong, Yuan Chen, Feng Ye, Shucai Zhang, Lejie Cao, Yun Fan, Gang Wu, Yubiao Guo, Chengzhi Zhou, Kewei Ma, Jian Fang, Weineng Feng, Yunpeng Liu, Zhendong Zheng, Gaofeng Li, Huijie Wang, Shundong Cang, Ning Wu, Wei Song, Xiaoqing Liu, Shijun Zhao, Lieming Ding, Giovanni Selvaggi, Yang Wang, Shanshan Xiao, Qian Wang, Zhilin Shen, Jianya Zhou, Jianying Zhou, Li Zhang
Updated overall survival and circulating tumor DNA analysis of ensartinib for crizotinib-refractory ALK-positive NSCLC from a phase II study. Cancer communications (London, England) 44 (4) (2024)
Fengqi Qiu, Peishan Jiang, Guiheng Zhang, Jie An, Kexin Ruan, Xiaowen Lyu, Jianya Zhou, Wanqiang Sheng
Priming with LSD1 inhibitors promotes the persistence and antitumor effect of adoptively transferred T cells. Nature communications 15 (1) (2024)
Fengqi Qiu, Peishan Jiang, Guiheng Zhang, Jie An, Kexin Ruan, Xiaowen Lyu, Jianya Zhou, Wanqiang Sheng
Priming with LSD1 inhibitors promotes the persistence and antitumor effect of adoptively transferred T cells. Nature communications 15 (1) (2024)
Cuihong Cai, Qian Shen, Jingjing Shao, Jingjing Qu, Shuangshuang Zhou, Jianya Zhou
Efficacy and Safety of Anlotinib in EGFR-Positive Patients with Advanced Lung Adenocarcinoma Compared with Chemotherapy: A Retrospective Study. Technology in cancer research & treatment 23 (2024)
Fengqi Qiu, Peishan Jiang, Guiheng Zhang, Jie An, Kexin Ruan, Xiaowen Lyu, Jianya Zhou, Wanqiang Sheng
Priming with LSD1 inhibitors promotes the persistence and antitumor effect of adoptively transferred T cells. Nature communications 15 (1) (2024)
Jing Zheng, Tao Wang, Yunpeng Yang, Jie Huang, Jifeng Feng, Wu Zhuang, Jianhua Chen, Jun Zhao, Wei Zhong, Yanqiu Zhao, Yiping Zhang, Yong Song, Yi Hu, Zhuang Yu, Youling Gong, Yuan Chen, Feng Ye, Shucai Zhang, Lejie Cao, Yun Fan, Gang Wu, Yubiao Guo, Chengzhi Zhou, Kewei Ma, Jian Fang, Weineng Feng, Yunpeng Liu, Zhendong Zheng, Gaofeng Li, Huijie Wang, Shundong Cang, Ning Wu, Wei Song, Xiaoqing Liu, Shijun Zhao, Lieming Ding, Giovanni Selvaggi, Yang Wang, Shanshan Xiao, Qian Wang, Zhilin Shen, Jianya Zhou, Jianying Zhou, Li Zhang
Updated overall survival and circulating tumor DNA analysis of ensartinib for crizotinib-refractory ALK-positive NSCLC from a phase II study. Cancer communications (London, England) (2024)
Wenjia Sun, Fengqi Qiu, Jing Zheng, Liangjie Fang, Jingjing Qu, Shumeng Zhang, Nan Jiang, Jianying Zhou, Xun Zeng, Jianya Zhou
CD57-positive CD8 + T cells define the response to anti-programmed cell death protein-1 immunotherapy in patients with advanced non-small cell lung cancer. NPJ precision oncology 8 (1) (2024)
Fengqi Qiu, Peishan Jiang, Guiheng Zhang, Jie An, Kexin Ruan, Xiaowen Lyu, Jianya Zhou, Wanqiang Sheng
Priming with LSD1 inhibitors promotes the persistence and antitumor effect of adoptively transferred T cells. Nature communications 15 (1) (2024)
Cuihong Cai, Qian Shen, Jingjing Shao, Jingjing Qu, Shuangshuang Zhou, Jianya Zhou
Efficacy and Safety of Anlotinib in EGFR-Positive Patients with Advanced Lung Adenocarcinoma Compared with Chemotherapy: A Retrospective Study. Technology in cancer research & treatment 23 (2024)
Wenjia Sun, Fengqi Qiu, Jing Zheng, Liangjie Fang, Jingjing Qu, Shumeng Zhang, Nan Jiang, Jianying Zhou, Xun Zeng, Jianya Zhou
CD57-positive CD8 + T cells define the response to anti-programmed cell death protein-1 immunotherapy in patients with advanced non-small cell lung cancer. NPJ precision oncology 8 (1) (2024)
Fengqi Qiu, Peishan Jiang, Guiheng Zhang, Jie An, Kexin Ruan, Xiaowen Lyu, Jianya Zhou, Wanqiang Sheng
Priming with LSD1 inhibitors promotes the persistence and antitumor effect of adoptively transferred T cells. Nature communications 15 (1) (2024)
Jing Zheng, Tao Wang, Yunpeng Yang, Jie Huang, Jifeng Feng, Wu Zhuang, Jianhua Chen, Jun Zhao, Wei Zhong, Yanqiu Zhao, Yiping Zhang, Yong Song, Yi Hu, Zhuang Yu, Youling Gong, Yuan Chen, Feng Ye, Shucai Zhang, Lejie Cao, Yun Fan, Gang Wu, Yubiao Guo, Chengzhi Zhou, Kewei Ma, Jian Fang, Weineng Feng, Yunpeng Liu, Zhendong Zheng, Gaofeng Li, Huijie Wang, Shundong Cang, Ning Wu, Wei Song, Xiaoqing Liu, Shijun Zhao, Lieming Ding, Giovanni Selvaggi, Yang Wang, Shanshan Xiao, Qian Wang, Zhilin Shen, Jianya Zhou, Jianying Zhou, Li Zhang
Updated overall survival and circulating tumor DNA analysis of ensartinib for crizotinib-refractory ALK-positive NSCLC from a phase II study. Cancer communications (London, England) 44 (4) (2024)
Fengqi Qiu, Peishan Jiang, Guiheng Zhang, Jie An, Kexin Ruan, Xiaowen Lyu, Jianya Zhou, Wanqiang Sheng
Priming with LSD1 inhibitors promotes the persistence and antitumor effect of adoptively transferred T cells. Nature communications 15 (1) (2024)
Wen-Xian Wang, Qian Wang, Chun-Wei Xu, Ziming Li, Zhengbo Song, Yong-Chang Zhang, Xiuyu Cai, Shi-Rong Zhang, Bin Lian, Wen Li, Anwen Liu, Ping Zhan, Hongbing Liu, Tangfeng Lv, Li-Yun Miao, Lingfeng Min, Yu Chen, Jingping Yuan, Feng Wang, Zhansheng Jiang, Gen Lin, Xingxiang Pu, Chuangzhou Rao, Dongqing Lv, Zongyang Yu, Xiaoyan Li, Chuanhao Tang, Cheng-Zhi Zhou, Congying Xie, Junping Zhang, Hui Guo, Qian Chu, Rui Meng, Jingxun Wu, Rui Zhang, Liping Wang, Youcai Zhu, Xiao Hu, Yanru Xie, Xinqing Lin, Jing Cai, Fen Lan, Huijing Feng, Lin Wang, Wang Yao, Xuefei Shi, Jianhui Huang, Huafei Chen, Yinbin Zhang, Pingli Sun, Bing Wan, Fei Pang, Zanmei Xu, Kai Wang, Yuanli Xia, Mingxiang Ye, Dong Wang, Qing Wei, Shuitu Feng, Jianya Zhou, Jiexia Zhang, Donglai Lv, Wenbin Gao, Jing Kang, Genhua Yu, Xianbin Liang, Chengtao Yu, Lin Shi, Nong Yang, Lin Wu, Zhuan Hong, Wei Hong, Meiyu Fang, Yiping Zhang, Yuanzhi Lu, Guansong Wang, Shenglin Ma, Lu Si, Wenfeng Fang, Yong Song
Chinese expert consensus on the multidisciplinary management of pneumonitis associated with immune checkpoint inhibitor. Thoracic cancer 13 (23) (2022)
Jingjing Qu, Farhin Shaheed Kalyani, Qian Shen, Guangdie Yang, Tianli Cheng, Li Liu, Jianya Zhou, Jian-Ying Zhou
Efficacy and Safety of PD-L1 Inhibitors plus Chemotherapy versus Chemotherapy Alone in First-Line Treatment of Extensive-Stage Small-Cell Lung Cancer: A Retrospective Real-World Study. Journal of oncology 2022 (2022)
Xi Chen, Liangjie Fang, Yanping Zhu, Zhang Bao, Qing Wang, Rong Liu, Wenjia Sun, Haiwei Du, Jing Lin, Bing Yu, Songan Chen, Jianya Zhou, Jianying Zhou
Blood tumor mutation burden can predict the clinical response to immune checkpoint inhibitors in advanced non-small cell lung cancer patients. Cancer immunology, immunotherapy : CII 70 (12) (2021)

Jianya Zhou.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Jianya Zhou